|
|
|
« BACK
NEWS & PRESS RELEASE ARCHIVES
Tuesday, May 31, 2005 :: IDSI ADDS SECOND RADIOLOGIST Monday, May 9, 2005 :: IDSI SIGNS 8TH CT LASER MAMMOGRAPHY SITE TO COMPLETE LUMINARY AND RESEARCH NETWORK Monday, April 11, 2005 :: SECOND CT LASER MAMMOGRAPHY REQUESTED BY POLAND’S LEADING CANCER CENTER Wednesday, March 30, 2005 :: IDSI Expands International Distribution Network To 20 Additional Countries Wednesday, March 30, 2005 :: NEW CT LASER MAMMOGRAPHY TECHNOLOGY FEATURED AT THE
IDSI ADDS SECOND RADIOLOGIST
TO MANAGE GROWING PHYSICIAN TRAINING DEMANDS
Fort Lauderdale, Florida, May 31, 2005—Imaging Diagnostic Systems, Inc., (OTCBB:IMDS) today announced the appointment of Jose A. Cisneros, M.D., Ph.D., to the Company’s clinical research team as Associate Director of Clinical Research. Dr. Cisneros, a radiologist and Ph.D. in biomedical engineering, will provide added depth to lead IDSI partnered research activities and expand physician-training programs.
IDSI had previously announced its intent to support multiple clinical partners in various countries as part of a global commercialization effort and to place additional CT Laser Mammography (CTLM®) systems in U.S. hospitals to gather studies for a Pre-Market Approval study.
Professor Eric Milne, M.D., IDSI Director of Clinical Research, commented, “I am delighted to welcome a very experienced and highly talented radiologist/bioengineer to IDSI and look forward with keen anticipation to working with him. I am confident that Dr. Cisneros’ extensive academic, clinical and industrial experience and his unique ability to operate across the interdisciplinary boundaries between image interpretation and image production, will add immeasurably to our research and development capabilities.”
Dr Cisneros most recently lead multi-modality physician education programs for Toshiba Medical Latin America and Picker International. He received his M.D. from Central University of Venezuela followed by residency training in radiology. After many years of practicing radiology he went on to complete Graduate studies in Medical Engineering at Massachusetts Institute of Technology. He received a Ph.D. in biomedical engineering from Drexel University, and then completed a Fellowship in Radiology and Ultrasound at Thomas Jefferson University where he was a member of the faculty.
The CTLMâ system is the first patented breast imaging system that utilizes state-of the-art laser technology and patented algorithms to create 3-D cross- sectional images of the breast. It is a non-invasive, painless examination that does not expose the patient to radiation or require breast compression. Imaging Diagnostic Systems has received CE Marking, CMDCAS (Canada), Canadian License, China SFDA approval, UL listing, ISO 9001:2000-13488 certification and FDA export certification for its CT Laser Breast Imaging system. The Company is seeking Pre-Market Approval (PMA) from the Food and Drug Administration (FDA) for its CTLMâ system to be used as an adjunct to mammography.
Please visit Imaging Diagnostic Systems’ website at: www.imds.com for additional information.
In conjunction with the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future anticipated projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates of future results and there can be no assurance that actual results will not materially differ from expectation. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company’s filing with the Securities Exchange Commission.
Investor Relations:
Rick Lutz
404-261-1196
lcgroup@mindspring.com
IDSI SIGNS 8TH CT LASER MAMMOGRAPHY SITE TO COMPLETE LUMINARY AND RESEARCH NETWORK
Fort Lauderdale, Florida, May 9, 2005—Imaging Diagnostic Systems, Inc., (OTCBB:IMDS) announced installation of the 8th luminary and research CT Laser Mammography system. The latest CTLM® was placed at the prestigious Gazi University Hospital, Ankara, Turkey where researchers have already begun breast scanning procedures.
A. Özdemir, M.D., Associate Professor, Department of Radiology, said, “We are anxious to show that the CT Laser Mammography technology substantially complements the conventionally used x-ray mammography, especially in the area of functional imaging. We have a lot of experience and expertise in early breast cancer detection especially in addressing the difficulties of imaging dense breasts where ultrasound may have been the preferred imaging technique. Our findings with CTLM may be of utmost importance for imaging centers seeking to stay current with the latest imaging developments.”
According to the Company the eight systems in this luminary network include:
Gazi University Hospital, Ankara, Turkey
Charles University Hospital, Prague, Czech Republic
Catholic University Hospital, Rome, Italy
Comprehensive Cancer Centre, Gliwice, Poland
Robert-Rössle Clinic, Buch, Germany
University of Muenster Hospital, Munster, Germany
Charite Hospital, Berlin, Germany
Vienna General Hospital, Vienna, Austria
Deborah O’Brien, Senior Vice President, said, “IDSI has been commercializing the CTLM in many global markets and we previously announced our plans to set up this network to foster research and to promote the technology in local markets. We will continue to support similar programs in China and in other global regions. These investments may accelerate CTLM market acceptance while providing valuable clinical experiences. With respect to Gazi, we are particularly pleased to have Professor Özdemir in our network to focus on using CTLM as an adjunct to current procedures.”
The CTLMâ system is the first patented breast imaging system that utilizes state-of the-art laser technology and patented algorithms to create 3-D cross- sectional images of the breast. It is a non-invasive, painless examination that does not expose the patient to radiation or require breast compression. Imaging Diagnostic Systems has received CE Marking, CMDCAS (Canada), Canadian License, China SFDA approval, UL listing, ISO 9001:2000-13488 certification and FDA export certification for its CT Laser Breast Imaging system. The Company is seeking PreMarket Approval (PMA) from the Food and Drug Administration (FDA) for its CTLMâ system to be used as an adjunct to mammography.
Please visit Imaging Diagnostic Systems’ website at: www.imds.com for additional information.
In conjunction with the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future anticipated projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates of future results and there can be no assurance that actual results will not materially differ from expectation. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company’s filing with the Securities Exchange Commission.
SECOND CT LASER MAMMOGRAPHY REQUESTED BY POLAND’S LEADING CANCER CENTER
Clinical Research Expected to Facilitate CTLM® Global Commercialization
Fort Lauderdale, Florida, April 11, 2005—Imaging Diagnostic Systems, Inc., (OTCBB:IMDS) announced that the company would fulfill a request by Professor B. Maciejewski, MD, PhD, FACR, Director of the Institute of Oncology, Center of Oncology, of the Maria Sklodowska-Curie Memorial Institute in Poland www.io.gliwice.pl to install a second CT Laser Mammography system for clinical research.
Professor Maciejewski noted that the additional CTLM was needed to “intensify the whole project”. The first system was installed in January 2005 and patient volumes have continued to increase.
“We are very pleased with the rapid acceptance of the CT laser breast imaging procedure among the women patients. Professor Maciejewski’s team has made an excellent effort to introduce CTLM to the region and to develop several research protocols that are of great interest to the Oncology Center and IDSI”, commented Deborah O’Brien, IDSI Senior Vice President.
The CTLMâ system is the first patented breast imaging system that utilizes state-of the-art laser technology and patented algorithms to create 3-D cross- sectional images of the breast. It is a non-invasive, painless examination that does not expose the patient to radiation or require breast compression. Imaging Diagnostic Systems has received CE Marking, CMDCAS (Canada), Canadian License, China SFDA approval, UL listing, ISO 9001:2000-13488 certification and FDA export certification for its CT Laser Breast Imaging system. The Company is seeking PreMarket Approval (PMA) from the Food and Drug Administration (FDA) for its CTLMâ system to be used as an adjunct to mammography.
Please visit Imaging Diagnostic Systems’ website at: www.imds.com for additional information.
In conjunction with the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future anticipated projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates of future results and there can be no assurance that actual results will not materially differ from expectation. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company’s filing with the Securities Exchange Commission.
Investor Relations:
Rick Lutz
404-261-1196
lcgroup@mindspring.com
Fort Lauderdale, Florida, March 28, 2005—Imaging Diagnostic Systems, Inc., (OTCBB:IMDS), announced that it has signed distribution agreements for 20 additional countries. The CT Laser Mammography (CTLM®) system was recently featured at two major trade exhibits: The Arab Health Meeting in Dubai and the European Congress of Radiology in Vienna. During these events, IDSI concluded negotiations to expand country coverage under their global commercialization program.
The countries added were Palestine, Jordan, Iran, Egypt, Libya, Tunisia, Azerbaijan, Tajikistan, Kazakhstan, Uzbekistan, and Georgia in the Middle East/N. Africa Region and Portugal, Slovenia, Latvia, Lithuania, Slovak Republic, Hungary, Ukraine and Byelorussia in the European Region. The Middle East/N. Africa Region is served by a hub in Ankara, Turkey, and includes existing distributors in Turkey, United Arab Emirates and Saudi Arabia. The European Region includes distributors in Italy, Poland, Czech Republic and Bulgaria.
Mr. Janusz Ostrowski, Vice President International Sales, commented, “Commercialization of the revolutionary CTLM laser breast imaging system is accelerating as a result of excellent reception at recent medical exhibitions. Over 85 people attended our Laser Mammography seminar in Vienna. Having established luminary research and reference relationships in the served areas has helped doctors and patients understand the importance of a device designed to reduce unnecessary and traumatic breast biopsies. With China anchoring our Asia Region, we are building the capability to cover all significant global markets. Of course, there is much more to accomplish this year.”
The CTLM system is the first patented breast imaging system that utilizes state-of the-art laser technology and patented algorithms to create 3-D cross- sectional images of the breast. It is a non-invasive, painless examination that does not expose the patient to radiation or require breast compression. Imaging Diagnostic Systems has received CE Marking, CMDCAS (Canada), Canadian License, China SFDA approval, UL listing, ISO 9001:2000-13488 certification and FDA export certification for its CT Laser Breast Imaging system. The Company is seeking PreMarket Approval (PMA) from the Food and Drug Administration (FDA) for its CTLM system to be used as an adjunct to mammography.
Please visit Imaging Diagnostic Systems’ website at: www.imds.com for additional information.
In conjunction with the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future anticipated projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates of future results and there can be no assurance that actual results will not materially differ from expectation. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company’s filing with the Securities Exchange Commission.
Investor Relations:
Rick Lutz
404-261-1196
lcgroup@mindspring.com
NEW CT LASER MAMMOGRAPHY TECHNOLOGY FEATURED AT THE
NATIONAL CONSORTIUM OF BREAST CENTERS CONFERENCE
Fort Lauderdale, Florida, March 2, 2005—Imaging Diagnostic Systems, Inc., (OTCBB:IMDS) announced today that it featured results from the CT Laser Mammography system (CTLM®) at the National Consortium of Breast Centers, Inc. 15th Annual National Interdisciplinary Breast Center Conference, Las Vegas, Nevada Feb. 27 to March 2nd, 2005.
The NCBC 2005 focus is “Breast Care: Defining Quality & Pursuing Excellence.” The conference presented over 60 nationally recognized speakers on breast cancer ranging from surgeons, radiologists, to the nurses, technologists and therapists. The exhibits featured an array of specialized technologies, equipment, products and services for breast centers, group practices and practitioners of breast care.
The National Consortium of Breast Centers, Inc. is a non-profit membership organization dedicated to excellence in breast health care for the general public. Members include breast health professionals who provide direct patient care and corporations and businesses that provide services or products to breast health professionals and their organizations. www.breastcare.org
The CTLMâ system is the first patented breast imaging system that utilizes state-of the-art laser technology and patented algorithms to create 3-D cross- sectional images of the breast. It is a non-invasive, painless examination that does not expose the patient to radiation or require breast compression. Imaging Diagnostic Systems has received CE Marking, CMDCAS (Canada), Canadian License, China SFDA approval, UL listing, ISO 9001:2000-13488 certification and FDA export certification for its CT Laser Breast Imaging system. The Company is seeking PreMarket Approval (PMA) from the Food and Drug Administration (FDA) for its CTLMâ system to be used as an adjunct to mammography.
Please visit Imaging Diagnostic Systems’ website at: www.imds.com for additional information.
In conjunction with the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future anticipated projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates of future results and there can be no assurance that actual results will not materially differ from expectation. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company’s filing with the Securities Exchange Commission.
Investor Relations:
Rick Lutz
404-261-1196
lcgroup@mindspring.com
